ABSTRACT
Obesity is associated with an increased risk of severe Covid-19. However, the effectiveness of SARS-CoV-2 vaccines in people with obesity is unknown. Here we studied the relationship between body mass index (BMI), hospitalization and mortality due to Covid-19 amongst 3.5 million people in Scotland. Vaccinated people with severe obesity (BMI>40 kg/m2) were significantly more likely to experience hospitalization or death from Covid-19. Excess risk increased with time since vaccination. To investigate the underlying mechanisms, we conducted a prospective longitudinal study of the immune response in a clinical cohort of vaccinated people with severe obesity. Compared with normal weight people, six months after their second vaccine dose, significantly more people with severe obesity had unquantifiable titres of neutralizing antibody against authentic SARS-CoV-2 virus, reduced frequencies of antigen-experienced SARS-CoV-2 Spike-binding B cells, and a dissociation between anti-Spike antibody levels and neutralizing capacity. Neutralizing capacity was restored by a third dose of vaccine, but again declined more rapidly in people with severe obesity. We demonstrate that waning of SARS-CoV-2 vaccine-induced humoral immunity is accelerated in people with severe obesity and associated with increased hospitalization and mortality from breakthrough infections. Given the prevalence of obesity, our findings have significant implications for global public health.
Competing Interest Statement
AS is a member of the Scottish Governments Standing Committee on Pandemic Preparedness and the Risk Stratification Subgroup of the UK Governments New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG). He was a member of AstraZenecas Thrombotic Thrombocytopenic Task Force. All roles are unremunerated. SJD is a Scientific Advisor to the Scottish Parliament on COVID-19 for which she receives a fee. All other authors have no conflict of interest to declare.
Funding Statement
The epidemiological study is part of the EAVE II project. EAVE II is funded by the MRC with the support of BREATHE The Health Data Research Hub for Respiratory Health which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through the Health Data Research UK. This research is part of the Data and Connectivity National Core Study led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation and the National Core Studies Immunity. Additional support has been provided through Public Health Scotland the Scottish Government Director-General Health and Social Care and the University of Edinburgh. The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme. The SCORPIO study was supported by the Medical Research Council (MR/W020564/1, a core award to J.E.T.; MC_UU_0025/12 and MR/T032413/1, an award to N.J.M.) and the Medical Research Foundation (MRF-057-0002-RG-THAV-C0798). Additional support was provided by NHSBT (WPA15-02 to N.J.M.), Addenbrookes Charitable Trust (900239 to N.J.M.) and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (N.J.M. and I.S.F.) and NIHR BioResource. M.A.L is supported by the Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0427, BBS/E/B/000C0428) and is a Lister Institute Fellow and an EMBO Young Investigator. I.M.H. is supported by a CIMR PhD studentship; H.J.S. by a Sir Henry Dale Fellowship jointly funded by Wellcome and the Royal Society [109407] and a BBSRC institutional programme grant [BBS/E/B/000C0433]. I.S.F. is supported by Wellcome (207462/Z/17/Z), Botnar Fondation, the Bernard Wolfe Health Neuroscience Endowment and a NIHR Senior Investigator Award. The PITCH study was funded by the UK Department of Health and Social Care. S.J.D. is funded by an NIHR Global Research Professorship (NIHR300791). P.K. is an NIHR Senior Investigator and is funded by Wellcome (WT109965MA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the National Research Ethics Service Committee, Southeast Scotland 02 (reference number: 12/SS/0201) for the study using the Early Pandemic Evaluation and Enhanced Surveillance of Covid-19 (EAVE II) platform. Clinical studies in people with severe obesity and normal weight controls were approved by the National Research Ethics Committee and Health Research Authority (East of England, Cambridge Research Ethics Committee (SCORPIO study, SARS-CoV-2 vaccination response in obesity amendment of NIHR BioResource 17/EE/0025)). Additional normal weight controls were recruited in Oxford, UK as part of the PITCH study under the GI Biobank Study 16/YH/0247, approved by Yorkshire & Humber Sheffield Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
